RUBY - ルビウス・セラピュ―ティクス (Rubius Therapeutics Inc.)

RUBYのニュース

   Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline  2020/08/10 12:00:00 GlobeNewswire
Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial Investigational New Drug Application…
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings  2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.
   Rubius Therapeutics to Announce First Quarter 2020 Financial Results  2020/05/04 20:01:00 GlobeNewswire
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is…
   The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation  2019/08/30 12:28:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ) NextCure Inc (NASDAQ: NXTC ) Radius Health Inc (NASDAQ: RDUS ) ResMed Inc. (NYSE: RMD ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks that hit 52-week lows on Aug. 30.) ContraFect Corp (NASDAQ: CFRX ) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) Rubius Therapeutics Inc (NASDAQ: RUBY ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Genmab-Novartis' Multiple Sclerosis Drug Found Superior To Sanofi's GENMAB A/S/S ADR (NASDAQ: GMAB ), which recently listed its shares in the U.S., said Novartis AG (NYSE: NVS ), its partner in the development of atumumab, has reported positive results … Full story available on Benzinga.com
   The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings  2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.
   Rubius Therapeutics to Announce First Quarter 2020 Financial Results  2020/05/04 20:01:00 GlobeNewswire
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is…
   The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation  2019/08/30 12:28:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ) NextCure Inc (NASDAQ: NXTC ) Radius Health Inc (NASDAQ: RDUS ) ResMed Inc. (NYSE: RMD ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks that hit 52-week lows on Aug. 30.) ContraFect Corp (NASDAQ: CFRX ) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) Rubius Therapeutics Inc (NASDAQ: RUBY ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Genmab-Novartis' Multiple Sclerosis Drug Found Superior To Sanofi's GENMAB A/S/S ADR (NASDAQ: GMAB ), which recently listed its shares in the U.S., said Novartis AG (NYSE: NVS ), its partner in the development of atumumab, has reported positive results … Full story available on Benzinga.com
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   Wells Fargo likes Molina after Investor Day  2019/05/31 12:41:50 Seeking Alpha
   Rubius Therapeutics to Announce First Quarter 2020 Financial Results  2020/05/04 20:01:00 GlobeNewswire
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is…
   The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation  2019/08/30 12:28:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ) NextCure Inc (NASDAQ: NXTC ) Radius Health Inc (NASDAQ: RDUS ) ResMed Inc. (NYSE: RMD ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks that hit 52-week lows on Aug. 30.) ContraFect Corp (NASDAQ: CFRX ) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) Rubius Therapeutics Inc (NASDAQ: RUBY ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Genmab-Novartis' Multiple Sclerosis Drug Found Superior To Sanofi's GENMAB A/S/S ADR (NASDAQ: GMAB ), which recently listed its shares in the U.S., said Novartis AG (NYSE: NVS ), its partner in the development of atumumab, has reported positive results … Full story available on Benzinga.com
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   Wells Fargo likes Molina after Investor Day  2019/05/31 12:41:50 Seeking Alpha
   Rubius Therapeutics misses by $0.01  2019/05/15 12:04:32 Seeking Alpha

calendar